NCT00441740 - Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

419

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Vinorelbine

Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles

DRUG

Gemcitabine

Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles

DRUG

Docetaxel

Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles

Trial Locations (9)

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Athens

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki